What Is forzinity: Research, Safety & Market Overview

forzinity is the brand name of the peptide drug elamipretide — the molecule long studied in mitochondrial biology under the code names ss-31, MTP-131 and Bendavia. On September 19, 2025, the U.S. FDA granted accelerated approval to forzinity for the Barth syndrome indication (improvement in muscle strength, in patients weighing at least 30 kg), making it the first approved therapy researched for this rare mitochondrial disease. This page is the hub of our forzinity research cluster: a summary of everything publicly documented about the brand, the molecule, the trials, the label data and the market — compiled for educational reference.

A second definition matters just as much. On this site, forzinity also names a search category: people look for its price, its side-effect data, its label, its regulatory status and how it relates to research-grade ss-31 sold by chemical suppliers. We organize all of that here. Nothing on this page or its cluster is medical advice, and nothing here directs anyone to acquire or use any pharmaceutical product; our disclaimer applies site-wide.

Elamipretide is a synthetic tetrapeptide — four amino-acid residues with an unusual aromatic one among them: D-Arg–2',6'-dimethyltyrosine–Lys–Phe–NH₂, with a molecular weight of about 639.8 Da for the free base. Its small size, cationic character and aromatic residue are what allow it to associate with anionic phospholipids of the inner mitochondrial membrane, a mechanism documented across two decades of preclinical literature. The full structural data is on our elamipretide structure page.

Published research suggests the peptide localizes to mitochondria and interacts with cardiolipin, the signature phospholipid of the inner membrane, with downstream effects on membrane stability, electron-transport-chain organization and reactive-oxygen-species production that studies show as ongoing research potential. Those mechanistic findings — and their limits — are summarized in our forzinity mechanism of action research review. The molecule-level view lives in our elamipretide research pillar, which is the second root of this site.

The FDA action of September 19, 2025 was an accelerated approval — a pathway that allows approval based on data reasonably likely to predict clinical benefit, while confirmatory studies continue. The forzinity approval rested on the TAZPOWER trial program in Barth syndrome, a rare, X-linked cardiolipin-remodeling deficiency with an estimated prevalence of a few cases per million. Orphan-drug economics, the label's weight threshold and the confirmatory-study obligations are all part of the public record documented on our forzinity fda page.

Outside the U.S., the picture is earlier-stage: European rights to elamipretide are licensed to Pharmanovia, with an EMA decision anticipated around mid-2027 per public reporting. The molecule's overall regulatory timeline — including the investigational-stage failures in other indications — is mapped on our elamipretide fda approval research page.

Barth syndrome is caused by loss-of-function variants in the TAZ gene, which encodes tafazzin, the enzyme that remodels cardiolipin. The mechanistic logic of studying an inner-membrane cardiolipin-binding peptide in a cardiolipin-remodeling disease is unusually direct, and the TAZPOWER program (including its 168-week extension observations) is the pivotal evidence base behind the accelerated approval. Published data demonstrates improvements in secondary measures of muscle strength and function, while primary-endpoint results were mixed across trial parts — a nuance we document honestly on the forzinity Barth syndrome research page.

The trial record matters to anyone assessing this molecule, because the same clinical program also investigated — and did not confirm benefit in — heart failure, mitochondrial myopathy and dry age-related macular degeneration. Our clinical trials pillar carries the complete global trial map, endpoint by endpoint.

The public forzinity label documents a 280 mg/3.5 mL (80 mg/mL) multi-dose vial for subcutaneous administration, with a labeled regimen of 40 mg daily; published renal-impairment data describe a 20 mg daily figure for the moderate-to-severe renal-impairment population. Storage is specified at 2–8°C with an 8-day in-use window after first puncture, and a terminal half-life around 4 hours is reported — consistent with the academic ss-31 pharmacokinetic literature. We reproduce these numbers as label documentation, not as guidance: read the forzinity dosage data and forzinity label pages for the full parameter tables.

Why does a research site care about label data? Because most of what people search for about forzinity — strength, storage, half-life, in-use dating — is label data, and the label is the single most checkable public document in the entire topic. Our data-usage instructions (below) explain how to cite it and how to spot when a secondary source has drifted from it.

The label's adverse-reaction data are dominated by injection-site events: erythema in 100% of labeled-population reporting, injection-site pain in 75%, and pruritus in 67% — figures that make local reactions the defining tolerability signal of the daily subcutaneous regimen. A separate laboratory signal, eosinophilia, appears in the label with onset associated with 30 or more days of exposure. We compile the frequencies, the monitoring language and the mechanistic research (including the MRGPRX2 mast-cell receptor work that may explain peptide injection reactions) on the safety overview and its detail pages on injection-site reactions and eosinophilia.

Across the broader elamipretide clinical literature — heart failure, myopathy, ophthalmology — the same pattern recurs: frequent local reactions, otherwise comparatively few discontinuations. That cross-trial record is summarized on our elamipretide side effects data page.

forzinity entered the market as one of the most expensive drugs by annualized cost: published list-price data (drugs.com) places a 14 mL supply at roughly $59,636. Because it is an orphan drug with a single specialty-pharmacy channel (AnovoRx) and a manufacturer support program (Mito Assist, 833-458-9099), the practical questions — assistance eligibility, coupon reality, insurance coverage, generic timeline — are all data questions. Our forzinity cost pillar is the hub for that entire cluster, including the patient assistance and forzinity coupons research pages.

The other half of the market picture is the research-grade channel: catalog suppliers sell ss-31-labeled elamipretide for laboratory use at research-chemical prices (published catalog references run roughly £30–94 per 10 mg). The two channels differ in regulation, documentation and legality — differences we quantify on the forzinity vs ss-31 comparison page.

The same tetrapeptide sequence exists in two entirely separate markets. The regulated channel is a prescription drug with a FDA-approved label, GMP manufacturing and a specialty-pharmacy supply chain. The research channel is a catalog chemical sold “for research use only,” with a certificate of analysis, no regulatory standing, and prices three orders of magnitude lower per milligram. Both facts are simultaneously true, and confusing them is the single most common category error in this topic space.

Our comparison pages do the arithmetic and the legal mapping without endorsing either channel: forzinity vs ss-31 compares mechanism identity, documentation, legal status and price; forzinity vs 2S50 does the same for the research-catalog designation. Neither page tells anyone to buy anything — they exist because the comparison questions are heavily searched and badly answered elsewhere.

The elamipretide clinical program is large for a peptide: double-blind studies in Barth syndrome heart failure (PROGRESS-HF), primary mitochondrial myopathy (MMPOWER-3), and dry age-related macular degeneration (ReCLAIM) all completed — and all missed their primary endpoints. Published data demonstrates that the molecule's research story is therefore genuinely mixed: one accelerated approval built on a rare-disease population, and several larger-population disappointments. We cover each program on its own page — heart failure, AMD — because honest negative results are part of the evidence base.

This mix is exactly why the molecule is scientifically interesting: effect sizes that reach significance in a homogeneous cardiolipin-deficiency population but not in broader cardiometabolic populations is a pattern consistent with a membrane-mechanism that needs a membrane defect. Hypotheses like that belong to the literature, and we label them as interpretation, not as data.

Every page in this cluster follows the same three-step discipline. First, extract the parameters: write down each number with its source, date and population — a 75% reaction frequency from the label is not interchangeable with a 75% from a trial abstract. Second, normalize before comparing: convert prices to the same unit basis, frequencies to the same population, and trial results to the same endpoint definitions. Third, grade the source: the FDA label outranks a press release, which outranks an aggregator, which outranks a forum post. Our editorial policy documents the full evidence hierarchy.

Where sources conflict — and in a fast-moving post-approval market they do — we date every figure and prefer the more specific, more recent, more checkable document. Price data in particular carries collection dates, because orphan-drug pricing moves.

This pillar anchors a cluster of twelve pages. Regulatory: FDA record and company profile. Science: mechanism of action, forzinity and elamipretide naming, and the comparison pages vs ss-31 and vs 2S50. Trials and label data: dosage data, Barth syndrome research, heart failure, AMD, and label summary. Safety: the four pages under side effects overview.

Every page links back here, and this page links to all of them — a closed hub-and-spoke topology that mirrors how Google's topic-cluster guidance expects authoritative content to be organized. The parallel elamipretide pillar is the molecule-level root; the clinical trials pillar and cost pillar complete the site map.